Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andriy Marusyk

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Biorxiv : the Preprint Server for Biology|September 26, 2025
Evolutionary antifragile therapyJeffrey West, Bina Desai, Maximilian Strobl, et al.
Scientific Reports|April 29, 2017
Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancerAndrew Dhawan, Daniel Nichol, Fumi Kinose, et al.
Medical Oncology (Northwood, London, England)|July 5, 2022
Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomesJason A Somarelli, James DeGregori, Marco Gerlinger, et al.
Cancer Research|May 22, 2026
Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexityJeffrey West, Bina Desai, Maximilian A R Strobl, et al.
Evolution, Medicine, and Public Health|December 11, 2024
Towards a new therapeutic approach based on selection for function in tumors: response to Dr. Mesut TezFrédéric Thomas, James DeGregori, Andriy Marusyk, et al.
Evolution, Medicine, and Public Health|October 4, 2024
A new perspective on tumor progression: Evolution via selection for functionFrédéric Thomas, James DeGregori, Andriy Marusyk, et al.
Science Advances|July 1, 2022
Measuring competitive exclusion in non-small cell lung cancerNathan Farrokhian, Jeff Maltas, Mina Dinh, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cyclesDaria Miroshnychenko, Tatiana Miti, Pragya Kumar, et al.
Cancer Research|October 4, 2023
Stroma-Mediated Breast Cancer Cell Proliferation Indirectly Drives Chemoresistance by Accelerating Tumor Recovery between Chemotherapy CyclesDaria Miroshnychenko, Tatiana Miti, Pragya Kumar, et al.
Mathematical Medicine and Biology : a Journal of the IMA|February 17, 2018
Simulated ablation for detection of cells impacting paracrine signalling in histology analysisJake P Taylor-King, Etienne Baratchart, Andrew Dhawan, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Biorxiv : the Preprint Server for Biology|September 26, 2025
Evolutionary antifragile therapyJeffrey West, Bina Desai, Maximilian Strobl, et al.
Scientific Reports|April 29, 2017
Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancerAndrew Dhawan, Daniel Nichol, Fumi Kinose, et al.
Medical Oncology (Northwood, London, England)|July 5, 2022
Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomesJason A Somarelli, James DeGregori, Marco Gerlinger, et al.
Cancer Research|May 22, 2026
Evolutionary antifragile therapy is a treatment strategy to suppress drug resistance by exploiting dose response convexityJeffrey West, Bina Desai, Maximilian A R Strobl, et al.
Evolution, Medicine, and Public Health|December 11, 2024
Towards a new therapeutic approach based on selection for function in tumors: response to Dr. Mesut TezFrédéric Thomas, James DeGregori, Andriy Marusyk, et al.
Evolution, Medicine, and Public Health|October 4, 2024
A new perspective on tumor progression: Evolution via selection for functionFrédéric Thomas, James DeGregori, Andriy Marusyk, et al.
Science Advances|July 1, 2022
Measuring competitive exclusion in non-small cell lung cancerNathan Farrokhian, Jeff Maltas, Mina Dinh, et al.
Biorxiv : the Preprint Server for Biology|February 17, 2023
Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cyclesDaria Miroshnychenko, Tatiana Miti, Pragya Kumar, et al.
Cancer Research|October 4, 2023
Stroma-Mediated Breast Cancer Cell Proliferation Indirectly Drives Chemoresistance by Accelerating Tumor Recovery between Chemotherapy CyclesDaria Miroshnychenko, Tatiana Miti, Pragya Kumar, et al.
Mathematical Medicine and Biology : a Journal of the IMA|February 17, 2018
Simulated ablation for detection of cells impacting paracrine signalling in histology analysisJake P Taylor-King, Etienne Baratchart, Andrew Dhawan, et al.
Pageof 8